Cited 0 times in
Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, C | - |
dc.contributor.author | Kim, C | - |
dc.contributor.author | Park, RW | - |
dc.contributor.author | Jeon, JY | - |
dc.date.accessioned | 2024-09-27T00:19:45Z | - |
dc.date.available | 2024-09-27T00:19:45Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 0884-0431 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/32799 | - |
dc.description.abstract | Both bisphosphonates and denosumab are the mainstays of treatment for osteoporosis to prevent fractures. However, there are still few trials directly comparing the prevention of fractures and the safety of 2 drugs in the treatment of osteoporosis. We aimed to compare the efficacy and safety between denosumab and bisphosphonates using a nationwide claims database. The database was covered with 10 million, 20% of the whole Korean population sampled by age and sex stratification of the Health Insurance Review and Assessment Service in South Korea. Among 228 367 subjects who were over 50 yr of age and taking denosumab or bisphosphonate from January 2018 to April 2022, the analysis was performed on 91 460 subjects after 1:1 propensity score matching. The primary outcome was treatment effectiveness; total fracture, major osteoporotic fracture, femur fracture, pelvic fracture, vertebral fracture, adverse drug reactions; acute kidney injury, chronic kidney disease, and atypical femoral fracture. Total fracture and osteoporotic major fracture, as the main outcomes of efficacy, were comparable in the denosumab and bisphosphonate group (HR 1.06, 95% CI, 0.98–1.15, P = .14; HR 1.13, 95% CI, 0.97–1.32, P = .12, respectively). Safety for acute kidney injury, chronic kidney disease, and atypical femoral fracture also did not show any differences between the 2 groups. In subgroup analysis according to ages, the denosumab group under 70 yr of age had a significantly lower risk for occurrences of acute kidney injury compared to the bisphosphonate group under 70 yr of age (HR 0.53, 95% CI, 0.29–0.93, P = .03). In real-world data reflecting clinical practice, denosumab and bisphosphonate showed comparable effectiveness for total fractures and major osteoporosis fractures, as well as safety regarding acute kidney injury, chronic kidney disease, and atypical femoral fracture. | - |
dc.language.iso | en | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Denosumab | - |
dc.subject.MESH | Diphosphonates | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis | - |
dc.subject.MESH | Osteoporotic Fractures | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea | - |
dc.type | Article | - |
dc.identifier.pmid | 38722817 | - |
dc.subject.keyword | antiresorptives | - |
dc.subject.keyword | fracture prevention | - |
dc.subject.keyword | general population studies | - |
dc.subject.keyword | osteoporosis | - |
dc.subject.keyword | statistical methods | - |
dc.contributor.affiliatedAuthor | Park, RW | - |
dc.contributor.affiliatedAuthor | Jeon, JY | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1093/jbmr/zjae070 | - |
dc.citation.title | Journal of bone and mineral research | - |
dc.citation.volume | 39 | - |
dc.citation.number | 7 | - |
dc.citation.date | 2024 | - |
dc.citation.startPage | 835 | - |
dc.citation.endPage | 843 | - |
dc.identifier.bibliographicCitation | Journal of bone and mineral research, 39(7). : 835-843, 2024 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1523-4681 | - |
dc.relation.journalid | J008840431 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.